Norwood Scale Staging: How Dermatologists Classify Male Pattern Hair Loss matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.
A friend of mine, 31, a project manager in Denver, texted me a photo of his crown last October. Taken under the fluorescent light in his office bathroom, slightly out of focus, slightly panicked. “Is this a Norwood 3? 4? Am I cooked?” He’d been Googling for two hours and had convinced himself he needed a transplant by Christmas. When he finally saw a dermatologist, she looked at his scalp for about ninety seconds, pulled up a dermoscope, and told him he was a solid Norwood 2 vertex with some early miniaturization. She started him on finasteride and told him to come back in six months. No transplant. Not even close.
That interaction captures something worth understanding: the Norwood scale is a simple tool that does a surprisingly difficult job. It has outlasted every competitor for half a century. Here’s why it matters, what it actually measures, and where it fits into real clinical decision-making.
A 70-Year-Old Framework That Still Works
James Hamilton published the foundational work on androgens and male hair loss in 1951 in the Annals of the New York Academy of Sciences. His key observation was almost accidentally elegant: men castrated before puberty didn’t develop the recession and crown thinning characteristic of androgenetic alopecia. Androgens were the driver.
O’Tar Norwood picked up Hamilton’s thread in 1975 in the Southern Medical Journal, expanding the original three-stage system into seven stages with variant subtypes (including the Type A variant, where loss marches backward from the front rather than following the classic bitemporal-plus-vertex pattern). The combined Hamilton-Norwood scale became the common language of hair loss classification.
Why has it survived? Partly because it’s good enough. It captures the major patterns men actually experience. Partly because it’s fast. A dermatologist can assign a stage in under a minute. And partly because its competitors, including the basic and specific (BASP) classification proposed in 2007, haven’t demonstrated enough added clinical value to justify the switch. Inertia matters in medicine, but this is the rare case where inertia and utility point in the same direction.
The comprehensive norwood scale overview walks through each stage with photographic examples, but understanding the biology behind the stages is what actually helps you make sense of your own situation.
The Biology: DHT, Miniaturization, and Why Some Follicles Die
The villain in pattern hair loss is dihydrotestosterone (DHT), a potent androgen that testosterone converts into via the 5-alpha reductase enzyme. In genetically susceptible follicles (and only in susceptible ones, which is why you keep your back-of-head hair), DHT binds to the androgen receptor in the dermal papilla and triggers a slow-motion collapse.
Each successive hair cycle, the anagen (growth) phase gets shorter. The telogen (resting) phase gets longer. The follicle itself physically shrinks. Thick terminal hairs become thin, short, unpigmented vellus hairs. Eventually they produce nothing visible at all. This process, follicular miniaturization, is what the Norwood scale is really tracking: not just where hair is gone, but where it’s actively on its way out.
The genetics are polygenic. The androgen receptor gene on the X chromosome gets the most press (hence the “look at your mom’s dad” folklore), but paternal genetics and multiple autosomal loci contribute meaningfully. Family history is directional, not deterministic. Some guys with bald fathers keep a full head of hair into their sixties. Some guys with no family history start thinning at 22.
How a Dermatologist Actually Evaluates You
If your entire hair loss evaluation consists of holding your phone over your head and comparing the photo to a chart on Reddit, you’re skipping most of what matters.
The American Academy of Dermatology’s clinical guidelines outline a structured workup: patient history, family history, scalp examination, trichoscopy, and selective lab testing. Each piece does something different.
History narrows the differential. Was the onset sudden or gradual? Diffuse or patterned? Any new medications, crash diets, major surgeries, or high fevers in the last three to six months? The timeline alone often separates androgenetic alopecia from telogen effluvium (temporary shedding after a physiological stressor).
Trichoscopy (basically a dermoscope on the scalp) reveals things invisible to the naked eye. In androgenetic alopecia, you see caliber variability of 20% or more between hair shafts, yellow dots from empty follicular ostia, and density loss in the frontal and vertex zones with preservation of the occipital donor area. That caliber variability, specifically, is one of the most reliable early signs.
Lab work is selective, not routine. Ferritin, thyroid stimulating hormone, vitamin D, and complete blood count are reasonable when diffuse thinning or telogen effluvium is suspected. The AAD does not recommend routine androgen panels in men with classic pattern loss because the diagnosis is clinical.
Standardized photography (front, top, sides, back, consistent distance and lighting) rounds out the evaluation. Without it, you’re relying on memory to judge whether treatment is working six months later, and memory is terrible at this.
Treatments, Ranked by Actual Evidence
Here’s the boring truth: the treatments with the best evidence for pattern hair loss are cheap pills and a topical solution that’s been available over the counter since the 1990s.
Oral finasteride (1 mg daily) has the strongest evidence base. The five-year randomized trial published in the Journal of the American Academy of Dermatology in 2002 showed sustained improvements in hair count versus placebo. Sexual side effects (reduced libido, erectile dysfunction) affect a small percentage of users in controlled trials and are generally reversible on discontinuation. The internet discourse around finasteride side effects runs hotter than the clinical data, which is worth keeping in mind without dismissing anyone’s individual experience.
Topical minoxidil 5% (twice daily) is FDA-approved for OTC use. The mechanism isn’t fully understood but involves potassium channel opening, vasodilation, and a direct effect on follicle cycling that prolongs anagen. Results typically become visible at three to six months. Generic costs $10 to $30 per month.
Low-dose oral minoxidil (0.25 to 5 mg daily) has gained traction since Vañó-Galván et al. published a multicenter safety study of 1,404 patients in JAAD in 2021. Side-effect profile at low doses is more manageable than the cardiovascular formulation’s reputation suggests, though periorbital edema and hypertrichosis are reported.
Dutasteride inhibits both type I and type II 5-alpha reductase isoforms, lowering DHT more aggressively than finasteride (Olsen et al., JAAD, 2006). It’s approved for benign prostatic hypertrophy and used off-label for hair loss. Head-to-head trials show larger hair density improvements, but the side-effect profile is also slightly broader.
PRP and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published smaller randomized trials with positive but variable findings (Gentile and Garcovich, Int J Mol Sci, 2020). Reasonable add-ons for selected patients. Not substitutes for medical therapy. At $500 to $1,500 per session with three to four sessions in the first year, the cost adds up fast.
Hair transplantation (FUE or FUT) physically moves follicles from the donor zone to the recipient area. In the US, FUE runs $4 to $10 per graft; a typical 2,500 to 3,500 graft case costs $10,000 to $35,000. Turkey clinics run $2,000 to $5,000 total for similar graft counts, reflecting labor cost differences. Transplant works best when the loss pattern has stabilized and the patient’s expectations are realistic. (My friend in Denver? Nowhere near needing one.)
Insurance generally classifies all of this as cosmetic and doesn’t cover it. HSA and FSA accounts may cover prescribed medications and physician visits but typically exclude surgical procedures.
What Actually Accelerates Loss (and What Doesn’t)
Androgenetic alopecia is genetically determined. Lifestyle modifies the timeline at the margins, not the fundamentals.
Smoking accelerates loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional data show higher rates of androgenetic alopecia in smokers versus matched nonsmokers.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium. Repleting iron in deficient patients reduces shedding. Supplementing iron in non-deficient patients does nothing.
Severe stress triggers telogen effluvium two to three months after the precipitating event, typically resolving in six to nine months. It doesn’t cause androgenetic alopecia, but it can unmask or accelerate it.
Anabolic steroid use pours gasoline on pattern hair loss through supraphysiologic androgen exposure, with effects that may not fully reverse after discontinuation.
Sleep deprivation has a small, clinically marginal effect through elevated cortisol and altered circadian regulation of the follicle cycle. It matters if it’s severe and sustained; a few bad nights won’t move the needle.
Crash diets and severe caloric restriction reliably produce telogen effluvium. Modest dietary changes don’t produce visible hair benefits beyond correcting specific deficiencies. No supplement stack is going to override your genetics.
When Self-Management Isn’t Enough
Several scenarios warrant an in-person dermatology visit rather than telehealth or self-assessment:
Sudden diffuse shedding that started within the last six months (likely telogen effluvium, needs workup). Patchy, smooth bald spots (alopecia areata, autoimmune, different treatment pathway). Scalp pain, burning, redness, scaling, or visible scarring (possible scarring alopecia like lichen planopilaris or frontal fibrosing alopecia, per Kassira et al., JAAD, 2017, which requires prompt diagnosis to prevent permanent follicle destruction). Hair loss in women with menstrual irregularities, acne, or excess body hair (warrants endocrine evaluation). Rapid progression, more than one Norwood stage per year in a young patient. Or simply: treatment that hasn’t worked after 12 months of documented use.
The AAD’s position is straightforward. Any progressive hair loss that concerns the patient is a legitimate reason for consultation. That’s a low bar, and it should be.
FAQs
Should I get a hair transplant if I am in my 20s?
Experienced surgeons approach transplantation in patients in their 20s cautiously because the long-term loss pattern isn’t established yet. Medical therapy to stabilize native hair comes first, almost always.
Is the Norwood scale used for women?
No. Female pattern hair loss is classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.
Can pattern hair loss be reversed?
Partially, in some patients, with early combination therapy (finasteride plus minoxidil). Late-stage loss with extensive follicular dropout is generally not reversible with medical therapy alone. Transplantation redistributes follicles but doesn’t create new ones.
What is shock loss after a hair transplant?
Temporary shedding of native or transplanted hairs in the weeks following surgery, typically resolving over three to six months as follicles re-enter the growth phase. It’s common and usually not cause for alarm.
How fast does pattern hair loss progress?
It varies enormously. Some men progress one Norwood stage every few years. Others remain stable for decades. Age of onset, family history, and rate of recent change are the strongest predictors.
Can stress cause permanent hair loss?
Severe stress causes telogen effluvium, which is temporary and typically resolves within six to nine months. Stress doesn’t directly cause androgenetic alopecia, though it can unmask underlying pattern loss in susceptible individuals.
Are supplements effective for pattern hair loss?
No supplement has strong evidence for treating androgenetic alopecia specifically. Correcting documented deficiencies (iron, vitamin D) can reduce shedding from telogen effluvium, but supplementation in non-deficient patients does not improve hair density.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
By
